Ambrx Biopharma Cayman, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
10975 North Torrey Pines Road, La Jolla, California
State of incorporation
Cayman Islands
Fiscal year end
December 31
Former names
Ambrx Biopharma Inc. (to 10/10/2023)
Latest financial report
Q2 2023 - Aug 9, 2023

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 434 M shares
Common Stock, Shares, Outstanding 432 M shares +59.9%
Entity Public Float 75.9 M USD
Common Stock, Value, Issued 43 K USD +59.3%
Weighted Average Number of Shares Outstanding, Basic 391 M shares +44.8%
Weighted Average Number of Shares Outstanding, Diluted 391 M shares +44.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.12 M USD -13.5%
Revenue from Contract with Customer, Excluding Assessed Tax 1.12 M USD -13.5%
Research and Development Expense 14.4 M USD -20.3%
General and Administrative Expense 5.9 M USD +22.3%
Operating Income (Loss) -19.2 M USD +33.4%
Nonoperating Income (Expense) 1.65 M USD +2325%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -17.5 M USD +39%
Income Tax Expense (Benefit) 305 K USD +136%
Net Income (Loss) Attributable to Parent -17.8 M USD +38.2%
Earnings Per Share, Basic -0.05 USD/shares +54.5%
Earnings Per Share, Diluted -0.05 USD/shares +54.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 228 M USD +248%
Cash, Cash Equivalents, and Short-term Investments 130 M USD
Accounts Receivable, after Allowance for Credit Loss, Current 81 K USD -94.5%
Other Assets, Current 981 K USD -0.51%
Assets, Current 241 M USD +99.5%
Property, Plant and Equipment, Net 3.2 M USD +1.56%
Operating Lease, Right-of-Use Asset 10 M USD -15.3%
Intangible Assets, Net (Excluding Goodwill) 24.9 M USD -2.46%
Other Assets, Noncurrent 357 K USD -23.4%
Assets 280 M USD +54.8%
Accounts Payable, Current 6.36 M USD +11.7%
Accrued Liabilities, Current 9.56 M USD -38.7%
Liabilities, Current 18.2 M USD -29.4%
Contract with Customer, Liability, Noncurrent 1.75 M USD -58.8%
Deferred Income Tax Liabilities, Net 880 K USD 0%
Operating Lease, Liability, Noncurrent 9.16 M USD -18.6%
Liabilities 29.6 M USD -24.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -953 K USD +5.36%
Retained Earnings (Accumulated Deficit) -325 M USD -22.5%
Stockholders' Equity Attributable to Parent 250 M USD +76.5%
Liabilities and Equity 280 M USD +54.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13 M USD +49.5%
Net Cash Provided by (Used in) Financing Activities 77.2 M USD
Net Cash Provided by (Used in) Investing Activities 29.6 M USD
Common Stock, Shares Authorized 950 M shares +90%
Common Stock, Shares, Issued 432 M shares +59.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 93.8 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 229 M USD +244%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 81.7 M USD +33.8%
Deferred Tax Assets, Gross 89.1 M USD +23.7%
Operating Lease, Liability 12 M USD -8.75%
Depreciation 200 K USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 14.7 M USD -11.3%
Property, Plant and Equipment, Gross 9.22 M USD +10%
Operating Lease, Liability, Current 1.85 M USD +40.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.9 M USD +2.91%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.81 M USD +50.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.68 M USD -21.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.98 M USD +2.97%
Deferred Tax Assets, Operating Loss Carryforwards 57.6 M USD +19.7%
Preferred Stock, Shares Issued 0 shares
Unrecognized Tax Benefits 4.73 M USD +70.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.07 M USD +2.99%
Operating Lease, Payments 673 K USD +227%
Additional Paid in Capital 576 M USD +41.2%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 200 K USD -50%
Deferred Tax Assets, Net of Valuation Allowance 80.8 M USD +34.3%
Share-based Payment Arrangement, Expense 2.89 M USD +53.6%